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A case of probable Amiodarone-induced pancreatitis in the treatment of
atrial fibrillation: a literature review and case report
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ABSTRACT
Amiodarone is an effective medication used in the treatment of several different arrhythmias.
Its most well-known adverse effects include pulmonary fibrosis, thyroid dysfunction, and
hepatotoxicity. A less common side effect is acute pancreatitis. A 67-year-old male being
treated for atrial fibrillation in rapid ventricular response with Amiodarone developed acute
epigastric abdominal pain 24 hours after initiation of therapy. He was diagnosed as having
acute pancreatitis based on characteristic findings seen on an abdominal CT scan. Commonly
encountered etiologies of pancreatitis were ruled out through a combination of the history,
laboratory values, and imaging results. Based on the temporal association of the acute
presentation and initiation of Amiodarone therapy, in conjunction with a lack of support
for any other etiology, the diagnosis of Amiodarone-induced pancreatitis was made. Within 7
days following the cessation of Amiodarone therapy, the patient’s symptoms had completely
resolved. Amiodarone-induced pancreatitis is an often overlooked medication association and
is one that has been infrequently reported throughout the literature. Given the substantial
morbidity and mortality associated with acute pancreatitis, and the ease of treatment (with-
drawing Amiodarone), this is a critical side effect that should be recognized in the appro-
priate clinical setting.
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1. Introduction
Amiodarone is a Class-III anti-arrhythmic medica-
tion that is used in the acute and chronic treatment
of various arrhythmias, including ventricular fibrilla-
tion, ventricular tachycardia, and atrial fibrillation.
Despite being effective as an antiarrhythmic, the
side effect profile seen with Amiodarone is extensive
and potentially fatal, which has limited its application
in medicine. The most common and well-studied side
effects of Amiodarone include pulmonary fibrosis,
hypo- or hyperthyroidism, hepatotoxicity, and per-
ipheral neuropathy. Pancreatitis is a very rare and
potentially fatal side effect associated with
Amiodarone, which has been infrequently reported
in literature [1–3]. We report a case of a patient who
developed acute pancreatitis following the initiation
of Amiodarone therapy.
2. Case presentation
A 67-year-old male presented to the hospital to
undergo radiofrequency ablation for symptomatic
atrial flutter. He tolerated the procedure well and
was transferred to the medical floor for bed rest
and standard overnight observation. The following
day, the patient developed symptomatic atrial fibril-
lation with rapid ventricular response and was
given one dose of intravenous Metoprolol as well
as oral Diltiazem for attempted rate control. This
did not adequately control his heart rate, and the
patient was subsequently transferred to an intensive
care unit for initiation of an Esmolol drip. During
the initial hours of the infusion, the patient became
extremely hypotensive, diaphoretic, and displayed
evidence of hypoperfusion. The patient was then
given a bolus of Amiodarone, started on pheny-
lephrine, and was eventually electrically cardio-
verted once his blood pressure stabilized. He was
then continued on an Amiodarone infusion over-
night and maintained normal sinus rhythm per
telemetry.
The following day, the patient began to develop
severe and sharp epigastric abdominal pain, without
signs or symptoms concerning for an acute abdomen.
A prompt evaluation with lab work, CT imaging, and
a gastroenterology evaluation was initiated.
Preliminary lab work was largely unremarkable,
demonstrating an amylase of 18, Lipase of 3, Lactate
of 1.0, AST of 19, and ALT of 15. CT imaging of the
abdomen demonstrated inflammation of the pancreas
that was consistent with acute pancreatitis (Figure 1).
Upon complete evaluation by a gastroenterologist,
the diagnosis of acute pancreatitis was made based
upon the classic presentation, along with CT
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radiographic evidence, despite normal amylase and
lipase. Given the timing of this acute presentation in
relation to Amiodarone, the etiology was speculated
to be Amiodarone induced. The Amiodarone drip
was immediately stopped, and management for
acute pancreatitis was continued, which included
judicious intravenous fluids and pain control. The
patent had an initial and dramatic improvement in
his pain, which had completely resolved by 1 week
following cessation of Amiodarone therapy.
3. Discussion
The diagnosis of acute pancreatitis can be made if
at least two of the following criteria are satisfied:
acute onset of severe epigastric pain that often
radiates to the back, elevations in serum amylase
or lipase to three times the upper limit of normal,
and characteristic findings of inflammation on
imaging [4]. The significance of this is that nor-
mal enzyme levels do not exclude the diagnosis,
and that when clinical suspicion is high, and the
other two criteria have been met, the diagnosis is
still made [5]. For our patient, the diagnosis of
acute pancreatitis was made based upon a history
and physical exam consistent with the disease and
characteristic findings seen on abdominal CT
scan, despite never having elevated enzyme levels.
Furthermore, our patient did not have a history of
previous pancreatitis episodes nor did he have any
common risk factors such as alcohol or drug
abuse. His history and investigations were also
negative for ductal dilation or gallstones seen on
CT, recent ERCP, trauma, infection, or laboratory
abnormalities suggestive of cholestasis or marked
hypertriglyceridemia. Of note, the patient had also
been given intravenous Metoprolol, which does
have a rare association with acute pancreatitis,
theorized to be in part due to profound hypertri-
glyceridemia [6]. In light of this, Amiodarone was
speculated to be the most likely catalyst for the
patient’s acute presentation due to its known asso-
ciation and initiation only 24 hours prior.
Drug-induced acute pancreatitis has no discern-
ibly different clinical presentation from pancreatitis
from other causes. Therefore, the diagnosis is made
if two of the diagnostic criteria are satisfied, all
other common etiologies are excluded, and there
is a temporal relationship with a known associated
medication. In the case of Amiodarone, the onset
of acute pancreatitis can occur as early as within
the first 3 days of treatment, or any time for years
after treatment initiation [7]. While the exact
mechanism remains unclear, it has been theorized
that the process is related to immunosuppression,
direct cellular cytotoxicity, pancreatic ductal con-
striction, or arterial thrombosis [8]. However,
regardless of the mechanism or etiology behind
the acute process, the treatment for pancreatitis
remains the same, with the most important aspect
of treatment being withdrawal of the offending
agent. Once the inciting therapy has been stopped,
symptoms typically resolve within 7–10 days and
do not recur without a second drug challenge. This
was the case with our patient as his entire acute
presentation completely resolved by the seventh
day following cessation of Amiodarone.
4. Conclusion
Even though the clinical presentation of
Amiodarone-induced pancreatitis is often milder
when compared to other etiologies, the disease
process still carries with it a significant morbidity
and mortality risk. Failure to identify Amiodarone
as the culprit will indubitably lead to continuation
of the offending agent, subsequent recurrences,
and potential worsening of the patient’s clinical
course. As such, despite being infrequently
reported in the literature, pancreatitis is an impor-
tant side effect and medication association that
should be recognized by the Internist and should
be investigated thoroughly in the appropriate clin-
ical setting.
Disclosure statement
No potential conflict of interest was reported by the
authors.
ORCID
Christopher J. Mercogliano http://orcid.org/0000-0003-
4336-7761
Figure 1. CT abdomen with contrast showing inflammation
of the body and tail of the pancreas. Findings consistent with
acute pancreatitis.
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